Lobbying Governance
| Overall Assessment | Analysis | Score |
|---|---|---|
| None |
Hikma Pharmaceuticals has an established governance structure for ethics and compliance, stating that its “Compliance, Responsibility and Ethics Committee … continued to promote and oversee our commitments to business integrity, quality, communities and ethical conduct” and that “Both Committee Chairs report all relevant matters considered by their Committees to the next Board meeting,” but it does not disclose any process to govern or align its external policy engagement. The company highlights that it “engaged in shaping US generic pharmaceutical policies and legislation as a member of the Association of Accessible Medicines,” and that it “regularly engage with US elected officials and policymakers,” yet provides no description of how these direct or indirect lobbying activities are reviewed or aligned with any policy, including climate goals. Moreover, when asked about processes to ensure consistency with climate commitments, the company states that “we are currently focusing our efforts and resources on managing our direct and indirect emissions” and confirms “No, and we do not plan to have one in the next two years” regarding any public commitment to align engagement activities with the Paris Agreement. We found no evidence of a policy, oversight sign-off, named individual or committee, or monitoring mechanism relating to lobbying governance or climate policy alignment.
View Sources
|
E |